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Combined diptheria-tetanus-pertussis (DTP)-killed poliovirus vaccine was used (along 
with bacille Calmette-Guérin, measles, yellow fever, and smallpox vaccines) in a routine 
immunization program in a rural area of Senegal. A control group in a neighboring 
region received D*rP vaccine without poliovirus vaccine. All immunizations were given 
at two sessions six months apart by a small mobile health team led by a nursc Six 
months a f t a  the second dose of DTP-polio vaccine, 97.4%,97.7%, and 90% of subjects 
two to eight months old at the start had detectable a n t i v y  to poliovirus types 1, 2, 
and 3, respectively. In the control group, SO%, 38%, and 80070 of such subjects had anti- 
body to poliovirus types 1. 2, and 3, respectively, acquired by natural infection during 
. _  
. .  
A-.-- - -  the study year. An average of 3.9 cases of paralytic poliomyelitis (range, one to 13) were 
observed annually at one dispensary in the test region from 1966 through 1979. From 
1980 through 1982, since the immunization program has b e n  in effect, only one case 
has been observed (in a nonimmunized child). 
The eight French-speaking countries of West 
Africa.&Benin, Ivory Coast, Mali, Mauritania, 
Niger,'Sènegal, Upper Volta. and Togo) are imple- 
menting Expanded Programmes on Immunization 
(EPI) as defined by the World Health Organiza- 
tion (WHO). Some of these programs have been 
successfully established in urban areas that can 
provide hxed centers with adequate refrigeration 
equipment and well-qualified staff. Only- 15%- 
20% of the population lives in such areas, how- 
ever; 80%-85% of the population has no practical 
access to medical care. It is therefore important to 
develop effective immunization programs for large 
rural populations. 
The West African countries, through their 
Organisation pour la Cooperation et la Coordina- 
tion pour la lutte contre les Grandes EndCmies 
(OCCGE), have given this goal a high priority and 
requested an evaluation of an immunization pro- 
gram that provides all EPI vaccinations in two 
field visits four to eight months apart. We placed 
particular emphasis on evaluating killed poliovirus 
vaccine, because reports from African countries 
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[1-3], India (41, and Israel (51 have documented 
low efficacy of oral; live poliovirus vaccine when 
used in routine immunization programs in tropical 
and subtropical countries. This problem has been 
overcome in some arcas by administering oral, live 
poliovirus vaccine in annual mass campaigns, but 
such campaigns are not practical in West Africa. 
We. report here an evaluation of killed poliovirus 
vaccine used in a routine immunization program. 
Methods 
A voluntary immunization program was begun in 
Kolda, a rural region of Senegal, in January 1980. 
The population of this area had not received vac- 
cinations for some time. All children two months 
to four years old were initially included, although 
the target population for first immunizations in 
the routine program includes primarily infants two 
to eight months of age The study reported here 
was carried out between April 1980, and April 
1981. 
Killed poliovirus vaccine was prepared by the 
Institut Merieux (Lyon, France) in accordance with 
the methods of van Wezel [a]. This vaccine was 
standardized against a reference vaccine [7] to con- 
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Ti~hlc. 1. Immunization schedules in Kolda and Scdhiou, 
Scncgal. T h e  second immunizat ion session occurrcd s is  
mon ths  af ter  the first.  -__ . . .- . . -. ._ - . ._ .--- - 
Immunization 
Agc -. 
rirsi session First Second 
Group (months) session session 
Kolda 2 - 8  DTP - polio DTP - polio 
BCG Measles 
Yellow fever 
Smallpox 
BCG Smallpox 
'Measles 
Yellow fever 
9-51  DTP - polio DTP - polio 
Sedhiou 2-51  DTP DTP . 
BCG S m a 1 I p o x 
NOTE. Smallpox vaccine was initially used as a marker for 
completion of vaccination; this practice is no longer in effect. 
The control group received killed poliovirus, measles, and yellow 
fever vaccines at the end of the study year. Abbreviation: 
DTP = diphtheria-tetanus-pertussis. 
tain 40, 4, and 16 D-antigen units of poliovirus 
types 1, 2, and 3, respectively. It was administered 
in the combination diphtheria-tetanus-pertussis 
(DTP)-polio vaccine. 
The vaccination team consisted of four persons 
Table 2. Comparison of test group (Kolda) and control 
group (Sedhiou) at the beginning of the study. 
Test Control 
Parameter WOUP group 
Age (months) 
2 - 8  1 20 116 
9 -  15 1 I5 116 
16-24 119 108 
25-51 120 106 
Total 414 446 
Male 222 205 
Female 252 24 I 
sex  
Nutritional status' 
Satisfactory 61 % 60% 
Poor 5 % 5 vo 
Intermediate 28% 35% 
Splenomegaly 16.5% 13.6% 
Hepatitis B antigen - positive 9% 10% 
Mortality data 
Live births per mother 4. I 3.8 
Surviving children per mother 2.8 2.6 
Child mortalityt 30.5% 30.9% 
See Methods. 
t Deaths of children younger than 10 years, as reported by 
mothers. 
'Table 3. Pcrccntage of childrcn in the [est group (Kolda) 
and  control group (Sedhiou)  with dctectnhlc poliovirus 
an t ibody (titers, 2114) the beginning of the study. . -~ .- . I - 
Percentage with antibody to 
indicated poliovirus type __ -- 
Type 3 _- .Type I Type 2 A!!? . - _  
(months) Test Control Test Control Test Control 
2 -  8 27.6 35.5 35.7 27.9 39.R 33.3 
I 24 44.4 42.9 26.0 25.7 32.2 52.4 
__ ._ .. - ._ - - - 
Y -  15 25.2 35.9 21.4 24.6 32.9 47.4 
- -51 61.8 62.8 66.1 58.7 61.7 61.7 - _I__ -- . 
Icd by a qualified nurse working under the super- 
vision of a physician in Kolda. Vaccines were kept 
refrigerated at 4 C in Kolda and carried to the field 
by the vaccination team using a vehicle equipped 
with a portable refrigerator. Temperature monitor- 
ing was carried out as part of a WHO cold-chain 
evaluation program. Vaccines were administered by 
jet injector, except for intradermal BCG injected 
by needle. 
During the one-year study period, m10,OOO chil- 
dren received a full set of vaccinations. Among 
these, ~ 5 0 0  children were selected for detailed clin- 
ical and serologic studies. A control group consist- 
ing of m500 chiIdren was selected from Sedhiou, a 
neighboring area where DTP was given but no 
polio vaccine. Immunization schedules for the dif- 
ferent groups are shown in table 1. Blood was 
obtained at the time of initial vaccination and 
again 12 months later (six months after the second 
immunization session) from 474 children in the 
test group and 449 children in the control group. A 
physician examined these study subjects at the 
initial vaccination session to evaluate nutritional 
status and splenomegaly. Physical parameters (age, 
weight, height, skin-fold thickness) were compared 
with NCHS (National Center for Health Statistics, 
Rockville, Md., USA) norms [SI: poor nutritional 
status was defined as values <70% of the norm, 
intermediate nutritional status as values 70%-80% 
of the norm, and satisfactory nutritional status as 
>8O% of the norm. Hepatitis B antigen was as- 
sayed in the initial serum sample. Titers of polio- 
virus, antibody were determined by virus neutral- 
ization tests performed at the Rijks Instituut voor 
de Volksgezondheid using Vero cells in microtiter 
plates and starting with a 1:2 serum dilution. 
Results 
The test and control groups were comparable with 
regard to age, sex, nutritional status, malaria 
Type 1 TY Pe 2 TY Pe 3 
a 2-8 months 
b 9-15 months 
c 16-24 months 
d 25-51 months 
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Figure 1. A, Percentage of children (by age groups) with titers of poliovirus antibody 21:4 at the start of the study 
(combined data from test and control groups). B, C, and D, Percentage of infants (two to eight months old at the 
start of the study) with the indicated titers of antibody to poliovirus types 1, 2, and 3, respectively. Antibody titers 
are shown as reciprocal of Semm dilution; H - - - H = test and control groups combined at  start of study; O- - - - -0 
= nonvaccinated controls 12 months after start of study; M= vaccinated children 12 months after start of 
study (six months after second dose of  killed poliovirus vaccine). 
(splenomegaly), and exposure to hepatitis B (table 
2). The general health of the two populations was 
equivalent, as indicated by mortality data. The 
initial titers of poliovirus antibody did not differ 
significantly between the test and control groups 
(table 3); these data are therefore combiyed in 
subsequent analyses on the initial bleeding. 
The age distribution, among all subjects, of 
those with poliovirus antibodies (titers 21:4) at the 
start of the study is shown in figure 1A. Maternal 
antibody against each of the three poliovirus types 
is present in 30%-40% of two- to eight-month-old 
infants; these levels decline until after 16 months 
of age, when the effect of natural infection with 
circulating wild poliovirus becomes evident. Sixty 
percent of two to four year olds have antibody to 
at least one of the three poliovirus types, a finding 
that indicates a high incidence of natural polio- 
virus infection in the study areas before the start of 
the immunization program. 
The distribution of antibody titers in vaccinated 
and control groups at the beginning and end of the 
study are shown in figures IB, lC, and 1D. Data for 
the two- to eight-month age group are shown here 
since that is the primary target population of the 
routine immunization program; similar responses 
were observed in all age groups. For both types 1 
and 2, the distribution patterns are clearly differ- 
ent in the vaccinated and control groups. Among 
vaccinated children, 97.4% and 97.7%, respec- 
tively, still have detectable antibody against polio- 
virus types 1 and 2 six months after the second 
dose of vaccine. Among the nonvaccinated chil- 
dren, only 50% and 38% have detectable antibody 
to types 1 and 2, respectively, due to infection with 
wild poliovirus during the study year. There was 
widespread circulation of type 3 poliovirus in the 
control group during this period, a situation result- 
ing in similar patterns of antibody distribution for 
the vaccinated and nonvaccinated children (figure 
1D). It is uncertain how much of the type 3 anti- 
body response in the vaccinated group is due to 
immunization and how much is due to natural 
infection; the temporal sequence of vaccination 
and possible infection is unknown. 
During the first three years of this voluntary 
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Figure 2. Number of cases of paralytic poliomyelitis 
seen at the Catholic Sisters Dispensary in Kolda, Senegal, 
1966- 1982. 
program, involving two visits by a mobile health 
team four to eight months apart, -26,000 children 
younger than four years of age were fully immu- 
nized. Surveys indicate that 75% of children three 
months to two years of age received at least one 
dose of poliovirus vaccine; 40% received two 
doses. The number of cases of paralytic poliomy- 
elitis observed at the Catholic Sisters Dispensary in 
Kolda is recorded by one nurse-sister who has been 
in charge for more than 17 years (figure 2). From 
1969 through 1979, there was an average of 3.9 
cases annually; after 1980 the effect of the immu- 
nization program is apparent. 
Discussion 
This study of killed poliovirus vaccine used in a 
routine immunization program reveals that almost 
all children show persistence of detectable antibody 
six months after two doses of vaccine administered 
six months apart. The vaccine used in this study 
contained 40, 4, and 16 D-antigen units of polio- 
virus types 1,2, and 3, respectively. Since 1981, the 
program has used a 40-8-32 D-antigen poliovirus 
vaccine that is expected to be effective against all 
three poliovirus types with a single dose [7]. 
In the Kolda region, there has been a marked 
decrease in the incidence of paralytic poliomyelitis 
observed at the only fixed health-care facility. 
Lameness surveys will be conducted for analyzing 
vaccine efficacy more thoroughly. 
Killed poliovirus vaccine has proven to be parti- 
cularly useful in a routine immunization program' 
in West Africa for several reasons. I t  induces 
prompt, reliable production of antibody, which is 
important in areas where wild poliovirus circulates 
freely and infections occur early in life. Killed 
poliovirus vaccine can be combined with other 
antigens, such as DTP, a practice that simplifies 
vaccine administration. Killed poliovirus vaccine 
requires normal refrigeration (4-8 C) rather than 
freezing. Potency of killed poliovirus vaccine can 
be adjusted to yield any desired response; studies 
are currently underway to determine the antigen 
content necessary to induce immunity with a single 
dose administered within the first few days of life. 
It is possible to reach a large rural population 
with a small mobile health team led by a nurse, 
using a vaccination schedule that involves only two 
visits per year for immunization against all the 
recommended EPI diseases: diphtheria, pertussis, 
tetanus, poliomyelitis, tuberculosis, measies, and 
yellow fever. Serologic studies of the vaccines for 
diseases other than poliomyelitis are underway. 
The program in Senegal is being expanded and 
similar two-dose immunization programs are being 
implemented in Mali and Upper Volta. 
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